Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$7.08 +0.4%	$9.85	$6.53 ▼ $30.60	$61.60M	2.89	145,904 shs	8,476 shs
PVLA Palvella Therapeutics	$24.40 +2.4%	$23.87	$6.20 ▼ $29.27	$269.77M	0.1	67,462 shs	5,496 shs
TERN Terns Pharmaceuticals	$3.14 +2.5%	$2.80	$1.87 ▼ $11.40	$274.59M	-0.16	1.52 million shs	123,214 shs
TSVT 2seventy bio	$5.00	$4.98	$2.29 ▼ $5.30	$266.15M	1.04	636,675 shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	-2.49%	-8.44%	-24.27%	-51.58%	-62.08%
PVLA Palvella Therapeutics	+3.88%	+3.61%	-3.01%	+26.42%	+2,382,999,900.00%
TERN Terns Pharmaceuticals	+1.66%	+2.34%	+4.08%	-17.07%	-51.58%
TSVT 2seventy bio	0.00%	0.00%	+0.20%	+100.00%	+17.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MCRB Seres Therapeutics	2.8742 of 5 stars	2.9	1.0	4.6	2.0	0.8	0.0
PVLA Palvella Therapeutics	3.9001 of 5 stars	4.6	0.0	0.0	2.9	4.2	0.6
TERN Terns Pharmaceuticals	4.0946 of 5 stars	3.3	1.0	4.1	4.3	2.5	0.6
TSVT 2seventy bio	1.2451 of 5 stars	0.9	4.0	0.0	2.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	1.80	Reduce	$73.67	940.49% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	89.70% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	398.41% Upside
TSVT 2seventy bio	1.80	Reduce	$4.25	-15.00% Downside

Current Analyst Ratings Breakdown

Latest MCRB, TSVT, TERN, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
3/26/2025	PVLA Palvella Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	$126.33M	0.49	N/A	N/A	($0.35) per share	-20.23
PVLA Palvella Therapeutics	$42.81M	6.30	N/A	N/A	$21.66 per share	1.13
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.13 per share	N/A
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	8/13/2025 (Estimated)
TERN Terns Pharmaceuticals	-$90.21M	-$1.09	N/A	N/A	N/A	N/A	-32.76%	-31.33%	8/4/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	8/6/2025 (Estimated)

Latest MCRB, TSVT, TERN, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
3/20/2025	Q4 2024	TERN Terns Pharmaceuticals	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	1.12	1.12
PVLA Palvella Therapeutics	N/A	4.82	4.82
TERN Terns Pharmaceuticals	N/A	32.99	32.99
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
PVLA Palvella Therapeutics	40.11%
TERN Terns Pharmaceuticals	98.26%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	4.70%
PVLA Palvella Therapeutics	20.50%
TERN Terns Pharmaceuticals	1.50%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	10.50 million	N/A
TERN Terns Pharmaceuticals	40	87.34 million	72.11 million	Not Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

MCRB, TSVT, TERN, and PVLA Headlines

Recent News About These Companies

2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Rating of "Reduce" by Brokerages

May 24, 2025 | americanbankingnews.com

2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Western Standard LLC

May 22, 2025 | marketbeat.com

Stonepine Capital Management LLC Has $882,000 Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT)

May 20, 2025 | marketbeat.com

Dimensional Fund Advisors LP Has $1.40 Million Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)

May 18, 2025 | marketbeat.com

Madison Avenue Partners LP Sells 1,983,327 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

May 16, 2025 | marketbeat.com

2seventy bio (NASDAQ:TSVT) Given "Sell (D-)" Rating at Weiss Ratings

May 12, 2025 | marketbeat.com

Engine Capital Management LP Sells 585,977 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

May 11, 2025 | marketbeat.com

DAFNA Capital Management LLC Sells 200,777 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

May 10, 2025 | marketbeat.com

2seventy bio (TSVT) Projected to Post Quarterly Earnings on Wednesday

May 9, 2025 | marketbeat.com

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025 | businesswire.com

Susquehanna Fundamental Investments LLC Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT)

May 7, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Marshall Wace LLP

May 3, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Given Average Recommendation of "Hold" by Brokerages

May 1, 2025 | marketbeat.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
By Leo Miller | May 19, 2025
View Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
These ETFs Provide Easy Exposure to Growing International Markets
By Nathan Reiff | May 24, 2025
View These ETFs Provide Easy Exposure to Growing International Markets
BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
By Jeffrey Neal Johnson | May 28, 2025
View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
By Leo Miller | May 13, 2025
View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%

MCRB, TSVT, TERN, and PVLA Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$7.08 +0.03 (+0.43%)

As of 11:51 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$24.40 +0.57 (+2.39%)

As of 11:22 AM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Terns Pharmaceuticals NASDAQ:TERN

$3.14 +0.08 (+2.45%)

As of 11:51 AM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)

As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time